Ridley Block Operations has initiated a voluntary recall of a single batch of its beef cattle feed product, Ultralyx 24% + 3% Mag Composite Block, because it contains elevated levels of non-protein nitrogen (NPN) that may be harmful to beef cattle.
Read The Complete Story!
Ridley Block Operations Announces Voluntary Recall of Ultralyx 24% + 3% Mag Composite
Ridley Block Operations has initiated a voluntary recall of a single batch of its beef cattle feed product, Ultralyx 24% + 3% Mag Composite Block, because it contains elevated levels of non-protein nitrogen (NPN) that may be harmful to beef cattle.
Read The Complete Story!
Thomas Hammer Coffee Roasters Inc. Issues Allergy Alert on Undeclared Milk, Egg, Soy, Wheat in The Cranberry Orange Scone
December 14th, 2016, Thomas Hammer Coffee Roasters Inc. of Spokane, Washington is recalling 52 Cranberry Orange Scones, because they may contain undeclared MILK, EGG, SOY, and WHEAT. People who have an allergy or severe sensitivity to MILK, EGG, SOY, WHEAT run the risk of serious or life-threatening allergic reaction if they consume this product.
H-E-B Issues Recall On Raw Shelled Pistachios
H-E-B announced today that it has issued a recall for both bulk and packaged raw shelled pistachios. The product is being removed because there is potential it could be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.
FDA approves Eucrisa for eczema
The U.S. Food and Drug Administration today approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.
FDA approves Eucrisa for eczema
The U.S. Food and Drug Administration today approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.
FDA Statement from Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, on new safety information on anesthesia use in young children and pregnant women
The health of our nation’s children is a responsibility that the FDA takes very seriously. Parents and caregivers are often concerned when their young child requires a medical procedure for which anesthesia or sedation drugs are necessary. Understandably, there are many questions, including whether the drugs are safe for their child. Pregnant women who must undergo medical procedures that require anesthesia or sedation drugs have similar concerns.
FDA Statement from Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, on new safety information on anesthesia use in young children and pregnant women
The health of our nation’s children is a responsibility that the FDA takes very seriously. Parents and caregivers are often concerned when their young child requires a medical procedure for which anesthesia or sedation drugs are necessary. Understandably, there are many questions, including whether the drugs are safe for their child. Pregnant women who must undergo medical procedures that require anesthesia or sedation drugs have similar concerns.
FDA takes action on applications seeking to market modified risk tobacco products
The U.S. Food and Drug Administration today took action on the first applications reviewed through the modified risk tobacco product (MRTP) pathway for eight Swedish Match North America Inc. snus smokeless tobacco products sold under the General brand name. The agency denied the company’s request to remove a currently required warning stating that the products can cause gum disease and tooth loss. With respect to the company’s other requests to remove or revise two additional currently required warnings, the agency deferred final action and issued a response that offers the company an option to amend its applications.
FDA takes action on applications seeking to market modified risk tobacco products
The U.S. Food and Drug Administration today took action on the first applications reviewed through the modified risk tobacco product (MRTP) pathway for eight Swedish Match North America Inc. snus smokeless tobacco products sold under the General brand name. The agency denied the company’s request to remove a currently required warning stating that the products can cause gum disease and tooth loss. With respect to the company’s other requests to remove or revise two additional currently required warnings, the agency deferred final action and issued a response that offers the company an option to amend its applications.